147416-96-4
147416-96-4 结构式
基本信息
Telenzepine dihydrochloide
TELENZEPINE DIHYDROCHLORIDE
JTQJFSQQHGPLOX-UHFFFAOYSA-N
Telenzepine hydrate dihydrochloride
TELENZEPINE DIHYDROCHLORIDE SELECTIVE M1 MUSCARIN
4,9-Dihydro-3-methyl-4-((4-methyl-1-piperazinyl)acetyl)-(10H)
4,9-Dihydro-3-methyl-4-((4-methyl-1-piperazinyl)acetyl)-(10H)thieno[3,4-b][1,5]benzodiazepin-10-onedihydrochloride
4,9-DIHYDRO-3-METHYL-4-[(4-METHYL-1-PIPERAZINYL)ACETYL]-10H-THIENO[3,4-B][1,5] BENZODIAZEPIN-10-ONE DIHYDROCHLORIDE
常见问题列表
Ki: 0.94 nM (Muscarinic M1 receptor), 17.8 nM (Muscarinic M2 receptor)
At submicromolar concentrations (100 nM), Telenzepine abolishes responses to either muscarine or the muscarinic component of the acetylcholine response. The excitatory effect of muscarine at postsynaptic M1 receptors is dose dependently inhibited by Telenzepine (0.1-1000 nM) at concentrations.
The threshold dose of Telenzepine as an antagonist of the muscarinic depolarization in AH/type 2 neurons is in the range of 0.1-1 nM. The IC
50
of Telenzepine needed to abolish the response is 8.5 nM.
Intravenous Telenzepine potently inhibits gastric acid secretion in the Ghosh-Schild rat (carbachol-stimulated), the chronic fistula rat (basal secretion), or, both intravenously and orally, in the modified Shay rat.
Telenzepine (2.7 μmol/kg; orally) treatment shows significantly longer duration antiulcer effects in the modified Shay rat.